Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Friedlander M, De Gramont A, Millward M, Bell D, Bugat R, Harnett P, Moreno J, Campbell L, Rippche V, Kayitalire L. Activity of Gemcitablne in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85054-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]

For:	Friedlander M, De Gramont A, Millward M, Bell D, Bugat R, Harnett P, Moreno J, Campbell L, Rippche V, Kayitalire L. Activity of Gemcitablne in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85054-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]

Number	Cited by Other Article(s)
1	Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2009;114:199-205. [DOI: 10.1016/j.ygyno.2009.04.026] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2009] [Revised: 04/17/2009] [Accepted: 04/20/2009] [Indexed: 10/20/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2009;114:199-205. [DOI: 10.1016/j.ygyno.2009.04.026] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2009] [Revised: 04/17/2009] [Accepted: 04/20/2009] [Indexed: 10/20/2022]